VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q1758880  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241221010816.0
008     241221nneanz||abbn n and d
035 ‎‡a  (WKP)Q1758880‏
024 ‎‡a  0000-0003-2061-0650‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q1758880‏
043 ‎‡c  US‏
046 ‎‡f  19411206‏
100 0 ‎‡a  Ronald Levy‏ ‎‡c  American oncologist‏ ‎‡9  en‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Ronald Levy‏ ‎‡c  oncólogo estadounidense‏ ‎‡9  es‏
400 0 ‎‡a  رونالد ليفي‏ ‎‡c  عالم أورام من الولايات المتحدة الأمريكية‏ ‎‡9  ar‏
400 0 ‎‡a  Роналд Леви‏ ‎‡9  ru‏
400 0 ‎‡a  Ronald Levy‏ ‎‡c  Amerikaans oncoloog‏ ‎‡9  nl‏
400 0 ‎‡a  Ronald Levy‏ ‎‡c  oncólogu estauxunidense‏ ‎‡9  ast‏
400 0 ‎‡a  Ronald Levy‏ ‎‡c  US-amerikanischer Onkologe‏ ‎‡9  de‏
400 0 ‎‡a  رونالد لوی‏ ‎‡9  fa‏
400 0 ‎‡a  Ronald Levy‏ ‎‡c  jamaikalainen pika-aitajuoksija‏ ‎‡9  fi‏
670 ‎‡a  Author's 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one‏
670 ‎‡a  Author's 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016‏
670 ‎‡a  Author's A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies‏
670 ‎‡a  Author's A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t‏
670 ‎‡a  Author's A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma‏
670 ‎‡a  Author's Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma‏
670 ‎‡a  Author's Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results‏
670 ‎‡a  Author's Active idiotypic vaccination versus control immunotherapy for follicular lymphoma‏
670 ‎‡a  Author's An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site‏
670 ‎‡a  Author's Antigen selection in human lymphomagenesis‏
670 ‎‡a  Author's B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification‏
670 ‎‡a  Author's BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma‏
670 ‎‡a  Author's CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies‏
670 ‎‡a  Author's CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity‏
670 ‎‡a  Author's Clinical relevance of immunologic phenotype in diffuse large cell lymphoma‏
670 ‎‡a  Author's Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection‏
670 ‎‡a  Author's Cytokine Fusion Constructs as DNA Vaccines Against Tumors‏
670 ‎‡a  Author's Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling‏
670 ‎‡a  Author's Diversity of T-cell antigen receptor variable genes used by mycosis fungoides cells‏
670 ‎‡a  Author's Enhancing immunotherapy of STING agonist for lymphoma in preclinical models‏
670 ‎‡a  Author's Eradication of spontaneous malignancy by local immunotherapy.‏
670 ‎‡a  Author's IDEC-C2B8‏
670 ‎‡a  Author's IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma‏
670 ‎‡a  Author's IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma‏
670 ‎‡a  Author's Identification of Peptide Ligands for the Antigen Binding Receptor Expressed on Human B-Cell Lymphomas‏
670 ‎‡a  Author's Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model‏
670 ‎‡a  Author's Immunomodulating antibodies and drugs for the treatment of hematological malignancies‏
670 ‎‡a  Author's Inhibition of lymphoma hybrids by human interferon‏
670 ‎‡a  Author's Interleukin 3 is a growth factor for human follicular B cell lymphoma‏
670 ‎‡a  Author's LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab‏
670 ‎‡a  Author's Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells‏
670 ‎‡a  Author's Pan-Leukocyte Monoclonal Antibody L3B12: Characterization and Application to Research and Diagnostic Prob‏
670 ‎‡a  Author's Pan-leukocyte monoclonal antibody L3B12. Characterization and application to research and diagnostic problems‏
670 ‎‡a  Author's Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.‏
670 ‎‡a  Author's Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma‏
670 ‎‡a  Author's Preliminary Observations on the Effect of Human Leukocyte Interferon in Non-Hodgkin's Lymphoma‏
670 ‎‡a  Author's Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma‏
670 ‎‡a  Author's Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma‏
670 ‎‡a  Author's Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer‏
670 ‎‡a  Author's The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow‏
670 ‎‡a  Author's The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile‏
670 ‎‡a  Author's Therapy of lymphoma directed at idiotypes‏
670 ‎‡a  Author's TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma‏
670 ‎‡a  Author's Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma‏
670 ‎‡a  Author's Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy‏
670 ‎‡a  Author's Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/processed/ISNI|0000000067120112‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/viaf/8694200‏
670 ‎‡a  wikidata authority control‏ ‎‡u  https://viaf.org/processed/LC|n 00121453‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://fi.wikipedia.org/wiki/Ronald_Levy‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://ar.wikipedia.org/wiki/رونالد_ليفي‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://fa.wikipedia.org/wiki/رونالد_لوی‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://de.wikipedia.org/wiki/Ronald_Levy‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://en.wikipedia.org/wiki/Ronald_Levy_(scientist)‏
670 ‎‡a  wikidata site links‏ ‎‡u  https://ru.wikipedia.org/wiki/Леви,_Рональд‏
909 ‎‡a  (orcid) 0000000320610650‏ ‎‡9  1‏
912 ‎‡a  31stannualmeetingandassociatedprogramsofthesocietyforimmunotherapyofcancersitc2016part2nationalharbor1500usa913november‏ ‎‡A  31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016‏ ‎‡9  1‏
912 ‎‡a  31stannualmeetingandassociatedprogramsofthesocietyforimmunotherapyofcancersitc2016part1‏ ‎‡A  31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one‏ ‎‡9  1‏
919 ‎‡a  submicroscopicinterstitialdeletionofchromosome14frequentlyoccursadjacenttothet‏ ‎‡A  A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t‏ ‎‡9  1‏
919 ‎‡a  humanthymusleukemiaantigendefinedbyhybridomamonoclonalantibodies‏ ‎‡A  A human thymus-leukemia antigen defined by hybridoma monoclonal antibodies‏ ‎‡9  1‏
919 ‎‡a  tumorresistanceinducedbysyngeneicbonemarrowtransplantationandenhancedbyinterleukin2amodelforthegraftversusleukemiareaction‏ ‎‡A  Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction‏ ‎‡9  1‏
919 ‎‡a  transferofspecificimmunitytobcelllymphomawithsyngeneicbonemarrowinmiceastrategyforusingautologousmarrowasanantitumortherapy‏ ‎‡A  Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy‏ ‎‡9  1‏
919 ‎‡a  timesincelastanticd20treatmentisamajordeterminantofsarscov2vaccineresponseinalargecohortofpatientswithbcelllymphoma‏ ‎‡A  Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma‏ ‎‡9  1‏
919 ‎‡a  tigitandpd1markintratumoraltcellswithreducedeffectorfunctioninbcellnonhodgkinlymphoma‏ ‎‡A  TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma‏ ‎‡9  1‏
919 ‎‡a  therapyoflymphomadirectedatidiotypes‏ ‎‡A  Therapy of lymphoma directed at idiotypes‏ ‎‡9  1‏
919 ‎‡a  t1418definesauniquesubsetofdiffuselargebcelllymphomawithagerminalcenterbcellgeneexpressionprofile‏ ‎‡A  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile‏ ‎‡9  1‏
919 ‎‡a  efficacyofhgalandlmo2intheseparationoflymphomasderivedfromsmallbcellsinnodalandextranodalsitesincludingthebonemarrow‏ ‎‡A  The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow‏ ‎‡9  1‏
919 ‎‡a  stimulationofnaturalkillercellswithacd137specificantibodyenhancestrastuzumabefficacyinxenotransplantmodelsofbreastcancer‏ ‎‡A  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer‏ ‎‡9  1‏
919 ‎‡a  rationaleforadjuvantidiotypicvaccinationafterhighdosetherapyformultiplemyeloma‏ ‎‡A  Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma‏ ‎‡9  1‏
919 ‎‡a  prolongeddiseasefreesurvivalandoverallsurvivalwithcvpalternatingwithfludarabineinadvancedfollicularlymphoma‏ ‎‡A  Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma‏ ‎‡9  1‏
919 ‎‡a  preliminaryobservationsontheeffectofhumanleukocyteinterferoninnonhodgkinslymphoma‏ ‎‡A  Preliminary Observations on the Effect of Human Leukocyte Interferon in Non-Hodgkin's Lymphoma‏ ‎‡9  1‏
919 ‎‡a  phase1clinicaltrialusingescalatingsingledoseinfusionofchimericanticd20monoclonalantibodyidecc2b8inpatientswithrecurrentbcelllymphoma‏ ‎‡A  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma‏ ‎‡9  1‏
919 ‎‡a  paraffinbased6genemodelpredictsoutcomeindiffuselargebcelllymphomapatientstreatedwithrchop‏ ‎‡A  Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.‏ ‎‡9  1‏
919 ‎‡a  panleukocytemonoclonalantibodyl3b12characterizationandapplicationtoresearchanddiagnosticproblems‏ ‎‡A  Pan-leukocyte monoclonal antibody L3B12. Characterization and application to research and diagnostic problems‏ ‎‡9  1‏
919 ‎‡a  panleukocytemonoclonalantibodyl3b12characterizationandapplicationtoresearchanddiagnosticprob‏ ‎‡A  Pan-Leukocyte Monoclonal Antibody L3B12: Characterization and Application to Research and Diagnostic Prob‏ ‎‡9  1‏
919 ‎‡a  monoclonalantiidiotypeantibodytherapyofbcelllymphomatheadditionofashortcourseofchemotherapydoesnotinterferewiththeantitumoreffectnorpreventtheemergenceofidiotypenegativevariantcells‏ ‎‡A  Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells‏ ‎‡9  1‏
919 ‎‡a  lmo2proteinexpressionpredictssurvivalinpatientswithdiffuselargebcelllymphomatreatedwithanthracyclinebasedchemotherapywithandwithoutrituximab‏ ‎‡A  LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab‏ ‎‡9  1‏
919 ‎‡a  interleukin3isagrowthfactorforhumanfollicularbcelllymphoma‏ ‎‡A  Interleukin 3 is a growth factor for human follicular B cell lymphoma‏ ‎‡9  1‏
919 ‎‡a  inhibitionoflymphomahybridsbyhumaninterferon‏ ‎‡A  Inhibition of lymphoma hybrids by human interferon‏ ‎‡9  1‏
919 ‎‡a  immunomodulatingantibodiesanddrugsforthetreatmentofhematologicalmalignancies‏ ‎‡A  Immunomodulating antibodies and drugs for the treatment of hematological malignancies‏ ‎‡9  1‏
919 ‎‡a  idiotypevaccinationpostbonemarrowtransplantationforbcelllymphomainitialstudiesinamurinemodel‏ ‎‡A  Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model‏ ‎‡9  1‏
919 ‎‡a  identificationofpeptideligandsfortheantigenbindingreceptorexpressedonhumanbcelllymphomas‏ ‎‡A  Identification of Peptide Ligands for the Antigen Binding Receptor Expressed on Human B-Cell Lymphomas‏ ‎‡9  1‏
919 ‎‡a  idecc2b8rituximabanticd20monoclonalantibodytherapyinpatientswithrelapsedlowgradenonhodgkinslymphoma‏ ‎‡A  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma‏ ‎‡9  1‏
919 ‎‡a  idecc2b8resultsofaphase1multipledosetrialinpatientswithrelapsednonhodgkinslymphoma‏ ‎‡A  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma‏ ‎‡9  1‏
919 ‎‡a  idecc2b8‏ ‎‡A  IDEC-C2B8‏ ‎‡9  1‏
919 ‎‡a  eradicationofspontaneousmalignancybylocalimmunotherapy‏ ‎‡A  Eradication of spontaneous malignancy by local immunotherapy.‏ ‎‡9  1‏
919 ‎‡a  enhancingimmunotherapyofstingagonistforlymphomainpreclinicalmodels‏ ‎‡A  Enhancing immunotherapy of STING agonist for lymphoma in preclinical models‏ ‎‡9  1‏
919 ‎‡a  diversityoftcellantigenreceptorvariablegenesusedbymycosisfungoidescells‏ ‎‡A  Diversity of T-cell antigen receptor variable genes used by mycosis fungoides cells‏ ‎‡9  1‏
919 ‎‡a  distinctpatternsofbcellreceptorsignalinginnonhodgkinlymphomasidentifiedbysinglecellprofiling‏ ‎‡A  Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling‏ ‎‡9  1‏
919 ‎‡a  cytokinefusionconstructsasdnavaccinesagainsttumors‏ ‎‡A  Cytokine Fusion Constructs as DNA Vaccines Against Tumors‏ ‎‡9  1‏
919 ‎‡a  clonalexpansioninfollicularlymphomaoccurssubsequenttoantigenicselection‏ ‎‡A  Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection‏ ‎‡9  1‏
919 ‎‡a  clinicalrelevanceofimmunologicphenotypeindiffuselargecelllymphoma‏ ‎‡A  Clinical relevance of immunologic phenotype in diffuse large cell lymphoma‏ ‎‡9  1‏
919 ‎‡a  cd20targetedtherapyablatesdenovoantibodyresponsetovaccinationbutsparespreestablishedimmunity‏ ‎‡A  CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity‏ ‎‡9  1‏
919 ‎‡a  cd137stimulationenhancestheantilymphomaactivityofanticd20antibodies‏ ‎‡A  CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies‏ ‎‡9  1‏
919 ‎‡a  bcl6genetranslocationinfollicularlymphomaaharbingerofeventualtransformationtodiffuseaggressivelymphoma‏ ‎‡A  BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma‏ ‎‡9  1‏
919 ‎‡a  blymphomacellsareactivatedbypeptideligandsoftheantigenbindingreceptororbyantiidiotypicantibodytoinduceextracellularacidification‏ ‎‡A  B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification‏ ‎‡9  1‏
919 ‎‡a  antigenselectioninhumanlymphomagenesis‏ ‎‡A  Antigen selection in human lymphomagenesis‏ ‎‡9  1‏
919 ‎‡a  epitopeonthetransferrinreceptorpreferentiallyexposedduringtumorprogressioninhumanlymphomaisclosetotheligandbindingsite‏ ‎‡A  An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site‏ ‎‡9  1‏
919 ‎‡a  activeidiotypicvaccinationversuscontrolimmunotherapyforfollicularlymphoma‏ ‎‡A  Active idiotypic vaccination versus control immunotherapy for follicular lymphoma‏ ‎‡9  1‏
919 ‎‡a  activeandpassiveimmunotherapyforlymphomaprovingprinciplesandimprovingresults‏ ‎‡A  Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results‏ ‎‡9  1‏
919 ‎‡a  activatingimmuneeffectorsanddampeningimmunesuppressorsgeneratessuccessfultherapeuticcancervaccinationinpatientswithlymphoma‏ ‎‡A  Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma‏ ‎‡9  1‏
919 ‎‡a  submicroscopicinterstitialdeletionofchromosome14frequentlyoccursadjacenttothet1418translocationbreakpointinhumanfollicularlymphoma‏ ‎‡A  A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma‏ ‎‡9  1‏
943 ‎‡a  201x‏ ‎‡A  2016‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
947 ‎‡a  US‏ ‎‡9  1‏
996 ‎‡2  J9U|987012922572005171‏
996 ‎‡2  BIBSYS|1470399607284‏
996 ‎‡2  RERO|A013355174‏
996 ‎‡2  NLA|000035275686‏
996 ‎‡2  SUDOC|279799977‏
996 ‎‡2  ISNI|0000000043940001‏
996 ‎‡2  ISNI|0000000392357009‏
996 ‎‡2  BNE|XX4818505‏
996 ‎‡2  NTA|184043433‏
996 ‎‡2  ISNI|0000000065077421‏
996 ‎‡2  SUDOC|075672952‏
996 ‎‡2  NUKAT|n 2004069247‏
996 ‎‡2  NUKAT|n 2017151264‏
996 ‎‡2  NII|DA07306563‏
996 ‎‡2  RERO|A026615679‏
996 ‎‡2  RERO|A003517562‏
996 ‎‡2  J9U|987007455968105171‏
996 ‎‡2  ISNI|0000000450975172‏
996 ‎‡2  SUDOC|14616816X‏
996 ‎‡2  J9U|987012798258005171‏
996 ‎‡2  DNB|1114421162‏
996 ‎‡2  ISNI|0000000454337100‏
996 ‎‡2  ISNI|0000000067120112‏
996 ‎‡2  BIBSYS|90339805‏
996 ‎‡2  LC|no 00057141‏
996 ‎‡2  ISNI|0000000388135913‏
996 ‎‡2  J9U|987011548676805171‏
996 ‎‡2  LC|n 00121453‏
996 ‎‡2  RERO|A023757787‏
996 ‎‡2  DBC|87097969575943‏
996 ‎‡2  LC|n 2016002781‏
996 ‎‡2  B2Q|0000026625‏
996 ‎‡2  ISNI|000000007384116X‏
996 ‎‡2  LC|n 2002162806‏
996 ‎‡2  BIBSYS|90536118‏
996 ‎‡2  NYNYRILM|54468‏
996 ‎‡2  RERO|A014361831‏
996 ‎‡2  LC|no2004101415‏
996 ‎‡2  CAOONL|ncf10727921‏
996 ‎‡2  LC|n 80132600‏
996 ‎‡2  J9U|987007388413005171‏
996 ‎‡2  BNF|16639491‏
996 ‎‡2  DNB|1056595116‏
996 ‎‡2  BNF|16094712‏
997 ‎‡a  1941 0 lived 1206 0‏ ‎‡9  1‏
998 ‎‡a  Ronald Levy‏ ‎‡c  American oncologist‏ ‎‡2  ISNI|0000000067120112‏ ‎‡3  suggested‏ ‎‡3  single date‏
998 ‎‡a  Levy, Ronald‏ ‎‡2  ISNI|0000000067120112‏ ‎‡3  suggested‏ ‎‡3  single date‏
998 ‎‡a  Levy, Ronald‏ ‎‡2  ISNI|0000000067120112‏ ‎‡3  suggested‏ ‎‡3  single date‏
998 ‎‡a  Levy, Ronald,‏ ‎‡2  NLA|000035275686‏ ‎‡3  single date‏
998 ‎‡a  Levy, Ronald,‏ ‎‡2  J9U|987007388413005171‏ ‎‡3  single date‏
998 ‎‡a  Levy, Ronald,‏ ‎‡2  LC|n 00121453‏ ‎‡3  suggested‏